Showing results (51-60 of 76) with videos related to
Sort By:
Pageof 8
Journal of Clinical Medicine|April 30, 2021
The Prognostic Role of Early Skeletal Muscle Mass Depletion in Multimodality Management of Patients with Advanced Gastric Cancer Treated with First Line Chemotherapy: A Pilot Experience from Modena Cancer CenterMargherita Rimini, Annarita Pecchi, Francesco Prampolini, et al.Oncotarget|April 19, 2017
GD2 expression in breast cancerGiulia Orsi, Monica Barbolini, Guido Ficarra, et al.European Journal of Cancer (Oxford, England : 1990)|June 21, 2021
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trialValentina Guarneri, Maria V Dieci, Gaia Griguolo, et al.Journal of the National Cancer Institute|September 7, 2023
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancerMaria Vittoria Dieci, PierFranco Conte, Giancarlo Bisagni, et al.Breast Cancer Research : BCR|June 23, 2018
Immune characterization of breast cancer metastases: prognostic implicationsMaria Vittoria Dieci, Vassilena Tsvetkova, Enrico Orvieto, et al.Biomarker Research|January 24, 2025
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypesClaudia Omarini, Virginia Catani, Ilenia Mastrolia, et al.The Oncologist|December 29, 2018
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast CancerElisabetta Pietri, Ilaria Massa, Sara Bravaccini, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancerValentina Guarneri, Daniele Giulio Generali, Antonio Frassoldati, et al.Breast Cancer Research and Treatment|August 10, 2007
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancerValentina Guarneri, Antonio Frassoldati, Guido Ficarra, et al.NPJ Breast Cancer|December 24, 2025
Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implicationsGaia Griguolo, Michele Bottosso, Laia Paré, et al.Pageof 8